Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003

被引:120
作者
Reinert, RR
Reinert, S
van der Linden, M
Cil, MY
Al-Lahham, A
Appelbaum, P
机构
[1] Univ Aachen, Inst Med Microbiol, Natl Referrence Ctr Streptocci, D-52057 Aachen, Germany
[2] SR Med Commun GmbH, Frechen, Germany
[3] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
关键词
D O I
10.1128/AAC.49.7.2903-2913.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Susceptibility testing results for Streptococcus pneumoniae isolates (n = 2,279) from eight European countries, examined in the PneumoWorld Study from 2001 to 2003, are presented. Overall, 24.6% of S. pneumoniae isolates were nonsusceptible to penicillin G and 28.0% were resistant to macrolides. The prevalence of resistance varied widely between European countries, with the highest rates of penicillin G and macrolide resistance reported from Spain and France. Serotype 14 was the leading serotype among penicillin G- and macrolide-resistant S. pneumoniae isolates. One strain (PW 158) showed a combination of an efflux type of resistance with a 23S rRNA mutation (A2061G, pneumococcal numbering; A2059G, Escherichia coli numbering). Six strains which showed negative results for mef(A) and erm (B) in repeated PCR assays had mutations in 23S rRNA or alterations in the L4 ribosomal protein (two strains). Fluoroquinolone resistance rates (levofloxacin MIC >= 4 mu g/ml) were low (Austria, 0%; Belgium, 0.7%; France, 0.9%; Germany, 0.4%; Italy, 1.3%; Portugal, 1.2%; Spain, 1.0%; and Switzerland, 0%). Analysis of quinolone resistance-determining regions showed eight strains with a Ser81 alteration in gyrA; 13 of 18 strains showed a Ser79 alteration in parC. The clonal profile, as analyzed by multilocus sequence typing (MLST), showed that the 18 fluoroquinolone-resistant strains were genetically heterogeneous. Seven of the 18 strains belonged to new sequence types not hitherto described in the MLST database. Europe-wide surveillance for monitoring of the further spread of these antibiotic-resistant S. pneumoniae clones is warranted.
引用
收藏
页码:2903 / 2913
页数:11
相关论文
共 59 条
[1]   Resistance among Streptococcus pneumoniae:: Implications for drug selection [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1613-1620
[2]   Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp nov. [J].
Arbique, JC ;
Poyart, C ;
Trieu-Cuot, P ;
Quesne, G ;
Carvalho, MDS ;
Steigerwalt, AG ;
Morey, RE ;
Jackson, D ;
Davidson, RJ ;
Facklam, RR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (10) :4686-4696
[3]   Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae [J].
Balsalobre, L ;
Ferrándiz, MJ ;
Liñares, J ;
Tubau, F ;
de la Carnpa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2072-2081
[4]   Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US study [J].
Brown, SD ;
Farrell, DJ ;
Morrissey, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (11) :4980-4987
[5]   Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae:: data from the global PROTEKT surveillance programme [J].
Canton, R ;
Morosini, M ;
Enright, MC ;
Morrissey, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :944-952
[6]   Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae [J].
Canu, A ;
Malbruny, B ;
Coquemont, M ;
Davies, TA ;
Appelbaum, PC ;
Leclercq, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :125-131
[7]   Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates [J].
Daly, MM ;
Doktor, S ;
Flamm, R ;
Shortridge, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (08) :3570-3574
[8]   In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae [J].
Davies, TA ;
Dewasse, BE ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :414-417
[9]   Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae [J].
Depardieu, F ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :319-323
[10]   A multilocus sequence typing scheme for Streptococcus pneumoniae:: identification of clones associated with serious invasive disease [J].
Enright, MC ;
Spratt, BG .
MICROBIOLOGY-UK, 1998, 144 :3049-3060